Table 3 Hospitalization/inpatient treatment
TNF inhibitor naive patients (n = 1,468) | TNF inhibitor continuing patients (n = 733) | |||||
|---|---|---|---|---|---|---|
Adalimumab (n = 669) | Etanercept (n = 628) | Infliximab (n = 171) | Adalimumab (n = 248) | Etanercept (n = 367) | Infliximab (n = 118) | |
Numbers of patients with at least hospitalization for any reason (%) | 522 | 498 | 126 | 190 | 278 | 86 |
78.03% | 79.30% | 73.68% | 76.61% | 75.75% | 72.88% | |
Numbers of patients with hospitalization related to RA | 298 | 290 | 66 | 95 | 162 | 47 |
44.54% | 46.18% | 38.60% | 38.31% | 44.14% | 39.83% | |